Farhad Ravandi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6042638/publications.pdf

Version: 2024-02-01

466	31,856	4103 90	8034 154
papers	citations	h-index	g-index

473	473	473	19412
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, .	2.0	11
2	Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline â€˜chemotherapy-freeâ€™ therapy. Leukemia and Lymphoma, 2022, 63, 672-675.	0.6	2
3	The cure of leukemia through the optimist's prism. Cancer, 2022, 128, 240-259.	2.0	17
4	Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. American Journal of Hematology, 2022, 97, 68-78.	2.0	25
5	Dr. Elihu H. Estey (1946â€“2021). American Journal of Hematology, 2022, 97, 166-167.	2.0	0
6	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 370-376.	1.3	8
7	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer Journal, 2022, 12, 10.	2.8	48
8	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12.	6.9	13
9	Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337.	2.0	15
10	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2022, 97, 574-582.	2.0	9
11	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia, 2022, 36, 1253-1260.	3.3	9
12	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American Journal of Hematology, 2022, 97, .	2.0	7
13	Is acute myeloid leukaemia maintenance therapy necessary?. Lancet Haematology,the, 2022, 9, e177-e178.	2.2	1
14	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864.	2.0	33
15	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	2.0	12
16	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers, 2022, 14, 150.	1.7	30
17	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	2.0	4
18	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	0.6	12

#	Article	IF	Citations
19	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer Journal, 2022, 12, 77.	2.8	33
20	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances, 2022, 6, 4006-4014.	2.5	37
21	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	2.0	31
22	Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer Journal, 2022, 12, .	2.8	9
23	A dynamic 3â€factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	2.0	7
24	Blinatumomab is associated with favorable outcomes in patients with Bâ€cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10^{â^'4} and higher. American Journal of Hematology, 2022, 97, 1135-1141.	2.0	6
25	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857.	0.8	41
26	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clinical Infectious Diseases, 2021, 72, 1755-1763.	2.9	48
27	Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145.	0.7	57
28	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia â€“ a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	0.6	6
29	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatmentâ€related mortality. American Journal of Hematology, 2021, 96, 282-291.	2.0	59
30	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	2.6	50
31	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1â€mutated acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1054-1063.	1.2	28
32	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 25.	2.8	85
33	Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal, 2021, 11, 41.	2.8	313
34	Decitabine and venetoclax for <scp>IDH1/2</scp>â€mutated acute myeloid leukemia. American Journal of Hematology, 2021, 96, E154-E157.	2.0	19
35	An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2021, 16, 89-96.	1.2	8
36	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 2021, 127, 1186-1207.	2.0	74

#	Article	IF	Citations
37	Outcome of Tâ€cell acute lymphoblastic leukemia/lymphoma: Focus on <scp>nearâ€ETP</scp> phenotype and differential impact of nelarabine. American Journal of Hematology, 2021, 96, 589-598.	2.0	42
38	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	2.0	24
39	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2021, 106, 2121-2130.	1.7	34
40	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer, 2021, 127, 2489-2499.	2.0	34
41	Acute lymphoblastic leukemia: A populationâ€based study of outcome in the <scp>U</scp>nited <scp>S</scp>tates based on the surveillance, epidemiology, and end results (<scp>SEER</scp>) database, <scp>1980</scp>â€“<scp>2017</scp>. American Journal of Hematology, 2021, 96, 650-658.	2.0	52
42	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer, 2021, 127, 2648-2656.	2.0	33
43	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia treated with hyperâ€CVAD and dasatinib. Cancer, 2021, 127, 2641-2647.	2.0	15
44	An effective chemotherapyâ€free regimen of ponatinib plus venetoclax for relapsed/refractory <scp>P</scp>hiladelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2021, 96, E229-E232.	2.0	17
45	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances, 2021, 5, 1876-1883.	2.5	56
46	De novo acute myeloid leukemia: A populationâ€based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer, 2021, 127, 2049-2061.	2.0	79
47	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature Communications, 2021, 12, 2607.	5.8	61
48	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. American Journal of Hematology, 2021, 96, 1000-1007.	2.0	23
49	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924.	2.0	13
50	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology, 2021, 11, 656218.	1.3	63
51	FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer Journal, 2021, 11, 104.	2.8	61
52	Current Approaches to Philadelphia Chromosomeâ€“Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Current Oncology Reports, 2021, 23, 95.	1.8	4
53	A phase 1b/2 study of azacitidine with PDâ€L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 3761-3771.	2.0	34
54	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Journal of Hematology and Oncology, 2021, 14, 94.	6.9	19

#	Article	IF	Citations
55	Therapeutic implications of menin inhibition in acute leukemias. Leukemia, 2021, 35, 2482-2495.	3.3	76
56	Acute promyelocytic leukemia current treatment algorithms. Blood Cancer Journal, 2021, 11, 123.	2.8	80
57	Hyperâ€CVAD plus ofatumumab versus hyperâ€CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosomeâ€"negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2021, 127, 3381-3389.	2.0	10
58	Outcomes of TP53â€mutant acute myeloid leukemia with decitabine and venetoclax. Cancer, 2021, 127, 3772-3781.	2.0	80
59	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer, 2021, 127, 4421-4431.	2.0	4
60	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Journal of Hematology and Oncology, 2021, 14, 133.	6.9	13
61	Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. Journal of Clinical Oncology, 2021, 39, 2535-2538.	0.8	14
62	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561.	2.2	81
63	Development of <scp>TP53</scp> mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	2.0	10
64	Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leukemia and Lymphoma, 2021, 62, 3402-3410.	0.6	12
65	Tenâ€day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity scoreâ€matched analysis. Cancer, 2021, 127, 4213-4220.	2.0	24
66	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162.	2.8	32
67	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419.	2.5	24
68	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 580-597.	0.2	28
69	Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. Journal of Hematology and Oncology, 2021, 14, 137.	6.9	33
70	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	0.8	173
71	Management of Relapsed/Refractory Acute Myeloid Leukemia. Hematologic Malignancies, 2021, , 89-109.	0.2	0
72	Editorial: Acute Promyelocytic Leukemia â€" Towards A Chemotherapy-Free Approach to Cure in All Patients. Frontiers in Oncology, 2021, 11, 831308.	1.3	5

#	Article	IF	Citations
73	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	2.0	25
74	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 212-218.	0.2	71
75	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	2.0	69
76	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Advances, 2020, 4, 5011-5024.	2.5	85
77	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. JAMA Oncology, 2020, 6, 1890.	3.4	207
78	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. Journal of Hematology and Oncology, 2020, 13, 132.	6.9	18
79	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	2.2	201
80	Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2775-2777.	0.6	4
81	Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leukemia and Lymphoma, 2020, 61, 3018-3020.	0.6	6
82	Phase 1 study of combinatorial sorafenib, <scp>Gâ€CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3â€ITD</scp>â€mutated acute myelogenous leukemia patients. American Journal of Hematology, 2020, 95, 1296-1303.	2.0	22
83	Survivorship in AML â€“ a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia and Lymphoma, 2020, 61, 3120-3127.	0.6	12
84	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315.	2.0	4
85	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. New England Journal of Medicine, 2020, 383, 2526-2537.	13.9	265
86	Antibody-basedÂtargeted therapies. Best Practice and Research in Clinical Haematology, 2020, 33, 101223.	0.7	0
87	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Advances, 2020, 4, 6117-6126.	2.5	29
88	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689.	2.5	105
89	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer Journal, 2020, 10, 48.	2.8	22
90	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica, 2020, 105, 1567-1574.	1.7	25

#	Article	IF	Citations
91	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer Journal, 2020, 10, 61.	2.8	20
92	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e871-e882.	0.2	10
93	Impact of TKIs postâ€"allogeneic hematopoietic cell transplantation in Philadelphia chromosomeâ€"positive ALL. Blood, 2020, 136, 1786-1789.	0.6	40
94	Identifying effective drug combinations for patients with acute myeloid leukemia. Expert Review of Anticancer Therapy, 2020, 20, 591-601.	1.1	4
95	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. Journal of Hematology and Oncology, 2020, 13, 70.	6.9	100
96	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	3.3	37
97	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622.	2.0	51
98	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discovery, 2020, 10, 506-525.	7.7	212
99	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Advances, 2020, 4, 1670-1677.	2.5	24
100	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	2.5	86
101	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	1.7	91
102	Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).. Journal of Clinical Oncology, 2020, 38, 7508-7508.	0.8	70
103	Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).. Journal of Clinical Oncology, 2020, 38, 7533-7533.	0.8	4
104	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539.	0.8	6
105	MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 37-48.	0.6	54
106	Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia. Expert Review of Hematology, 2019, 12, 707-714.	1.0	5
107	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€"positive acute myeloid leukemia. Cancer, 2019, 125, 3755-3766.	2.0	38
108	How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. Haematologica, 2019, 104, 1532-1541.	1.7	37

#	Article	IF	Citations
109	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395.	2.0	26
110	Current and emerging treatments for acute promyelocytic leukemia. Expert Opinion on Orphan Drugs, 2019, 7, 453-461.	0.5	1
111	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematology,the, 2019, 6, e480-e488.	2.2	103
112	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Current Treatment Options in Oncology, 2019, 20, 4.	1.3	50
113	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2019, 10, 204062071984949.	1.1	18
114	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer, 2019, 125, 3219-3224.	2.0	14
115	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	2.0	32
116	10-day vs 5-day decitabine: equivalence cannot be concluded â€“ Authors' reply. Lancet Haematology,the, 2019, 6, e178.	2.2	4
117	FLT3inhibitor quizartinib (AC220). Leukemia and Lymphoma, 2019, 60, 1866-1876.	0.6	15
118	Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586.	2.0	63
119	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190.	2.0	4
120	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	0.6	393
121	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Therapeutic Advances in Hematology, 2019, 10, 204062071982731.	1.1	93
122	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	2.5	84
123	Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. Future Oncology, 2019, 15, 3885-3894.	1.1	2
124	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica, 2019, 104, 305-311.	1.7	56
125	Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 142-148.e1.	0.2	39
126	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84

#	Article	IF	Citations
127	How I treat Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood, 2019, 133, 130-136.	0.6	62
128	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications, 2019, 10, 244.	5.8	111
129	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	6.9	257
130	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer Journal, 2019, 9, 7.	2.8	64
131	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. American Journal of Hematology, 2019, 94, 257-265.	2.0	99
132	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3â€internal tandem duplication genotypes. Cancer, 2019, 125, 1091-1100.	2.0	50
133	The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481.	2.0	229
134	Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemiaâ€"A case report. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 161-165.	0.6	3
135	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2647-2647.	0.6	11
136	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). Blood, 2019, 134, 290-290.	0.6	19
137	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTEÂ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood, 2019, 134, 833-833.	0.6	55
138	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood, 2019, 134, 830-830.	0.6	38
139	Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, 7034-7034.	0.8	8
140	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer, 2018, 124, 2534-2540.	2.0	23
141	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood, 2018, 131, 2782-2788.	0.6	18
142	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 257-265.	0.2	39
143	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248.	5.1	192
144	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 91-99.	1.2	15

#	Article	IF	Citations
145	FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. American Journal of Hematology, 2018, 93, 553-563.	2.0	13
146	A phase I study of moxetumomab pasudotox in adults with relapsed or refractory Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 182, 442-444.	1.2	11
147	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 813-820.	0.6	16
148	Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99.	2.0	74
149	Current paradigms in the management of <scp>P</scp>hiladelphia chromosome positive acute lymphoblastic leukemia in adults. American Journal of Hematology, 2018, 93, 286-295.	2.0	38
150	Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e19-e25.	0.2	14
151	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Miniâ€“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230.	3.4	124
152	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. American Journal of Hematology, 2018, 93, 371-374.	2.0	68
153	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood, 2018, 131, 387-396.	0.6	131
154	Clinical experience with the <scp>BCL</scp>2â€inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology, 2018, 93, 401-407.	2.0	336
155	Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. American Journal of Surgical Pathology, 2018, 42, 569-577.	2.1	9
156	Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33+disease?. Advances in Cell and Gene Therapy, 2018, 1, e21.	0.6	0
157	Treatment of Acute Promyelocytic Leukemia With No or Minimal Chemotherapy: Now a Reality in Common Clinical Practice. Journal of Oncology Practice, 2018, 14, 663-664.	2.5	3
158	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1788-1797.	0.8	156
159	Evaluating measurable residual disease in acute myeloid leukemia. Blood Advances, 2018, 2, 1356-1366.	2.5	132
160	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematology,the, 2018, 5, e618-e627.	2.2	190
161	Is it time to routinely incorporate MRD into practice?. Best Practice and Research in Clinical Haematology, 2018, 31, 396-400.	0.7	7
162	Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€hyperâ€CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first salvage. Cancer, 2018, 124, 4044-4055.	2.0	88

#	Article	IF	Citations
163	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leukemia Research, 2018, 73, 78-85.	0.4	9
164	MRD in HCL: does it matter?. Blood, 2018, 131, 2277-2278.	0.6	6
165	Phase 3 results for vosaroxin/cytarabine in the subset of patients â‰¥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica, 2018, 103, e514-e518.	1.7	9
166	Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Modern Pathology, 2018, 31, 1717-1732.	2.9	30
167	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018, 132, 1125-1133.	0.6	60
168	Hairy Cell Leukemia. , 2018, , 1265-1276.		1
169	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia, 2018, 32, 1768-1777.	3.3	184
170	Sorafenib Combined with 5â€azacytidine in Older Patients with Untreated FLT3â€ITD Mutated Acute Myeloid Leukemia. American Journal of Hematology, 2018, 93, 1136-1141.	2.0	95
171	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematology,the, 2018, 5, e411-e421.	2.2	66
172	Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia, 2018, 32, 2698-2701.	3.3	20
173	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 286-286.	0.6	19
174	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 905-905.	0.6	21
175	Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (â‰65 yrs) with Acute Myeloid Leukemia. Blood, 2018, 132, 4039-4039.	0.6	1
176	Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study. Blood, 2018, 132, 763-763.	0.6	43
177	Frontline treatment of acute myeloid leukemia in adults. Critical Reviews in Oncology/Hematology, 2017, 110, 20-34.	2.0	105
178	How I manage patients with hairy cell leukaemia. British Journal of Haematology, 2017, 177, 543-556.	1.2	28
179	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 845-850.	2.0	36
180	Factors associated with risk of central nervous system relapse in patients with nonâ€core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 924-928.	2.0	17

#	Article	IF	Citations
181	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyperâ€CVADâ€based regimens. Cancer, 2017, 123, 3717-3724.	2.0	18
182	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Advances in Experimental Medicine and Biology, 2017, 995, 73-95.	0.8	31
183	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer, 2017, 123, 3050-3060.	2.0	47
184	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	0.6	193
185	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581.	0.6	285
186	Poor outcomes associated with +der(22)t(9;22) and â^'9/9p in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology, 2017, 92, 238-243.	2.0	41
187	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	0.6	214
188	<scp>S</scp>ignificance of recurrence of minimal residual disease detected by multiâ€parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. American Journal of Hematology, 2017, 92, 279-285.	2.0	32
189	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. American Journal of Hematology, 2017, 92, 331-337.	2.0	39
190	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica, 2017, 102, 1709-1717.	1.7	13
191	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439.	2.0	37
192	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	2.0	114
193	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood, 2017, 130, 1514-1522.	0.6	151
194	Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. Expert Review of Hematology, 2017, 10, 863-874.	1.0	16
195	Acute Promyelocytic Leukemia: A Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 543-544.	0.2	14
196	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. Best Practice and Research in Clinical Haematology, 2017, 30, 193-200.	0.7	27
197	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <scp>B</scp>â€cell acute lymphoblastic leukemia. Cancer, 2017, 123, 294-302.	2.0	70
198	Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp>hiladelphia chromosomeâ€"negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	2.0	49

#	Article	IF	Citations
199	Targeting acute myeloid leukemia with TP53-independent vosaroxin. Future Oncology, 2017, 13, 125-133.	1.1	5
200	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer, 2017, 123, 426-435.	2.0	63
201	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances, 2017, 1, 1312-1323.	2.5	83
202	Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation. Hematology American Society of Hematology Education Program, 2017, 2017, 22-27.	0.9	29
203	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2017, 18, 1618.	1.8	37
204	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2017, 130, 815-815.	0.6	11
205	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. Journal of Clinical Oncology, 2017, 35, 7013-7013.	0.8	18
206	CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, TPS7066-TPS7066.	0.8	7
207	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances, 2016, 1, 250-259.	2.5	142
208	Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e302-e312.	1.8	8
209	Longâ€term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. British Journal of Haematology, 2016, 174, 760-766.	1.2	76
210	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). American Journal of Hematology, 2016, 91, 227-232.	2.0	46
211	Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology, 2016, 91, 385-389.	2.0	4
212	Final results of a single institution experience with a pediatricâ€based regimen, the augmented Berlinâ€“Frankfurtâ€“MÃ¼nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyperâ€CVAD regimen. American Journal of Hematology, 2016, 91, 819-823.	2.0	102
213	Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemia. Expert Opinion on Orphan Drugs, 2016, 4, 885-892.	0.5	2
214	Alemtuzumab in T-cell large granular lymphocyte leukaemia. Lancet Haematology,the, 2016, 3, e4-e5.	2.2	2
215	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITDâ€“Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1218-1226.	2.0	66
216	The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. Expert Review of Hematology, 2016, 9, 529-534.	1.0	7

#	Article	IF	Citations
217	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood, 2016, 127, 1863-1869.	0.6	253
218	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2016, 122, 3812-3820.	2.0	17
219	Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S25-S29.	0.2	28
220	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology, 2016, 91, 1221-1226.	2.0	12
221	Hyperâ€CVAD plus ponatinib versus hyperâ€CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122, 3650-3656.	2.0	156
222	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 616-624.	0.2	11
223	A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research, 2016, 48, 92-100.	0.4	45
224	Impact of complete molecular response on survival in patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood, 2016, 128, 504-507.	0.6	194
225	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	2.0	200
226	Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	1.2	102
227	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 163-168.e2.	0.2	18
228	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 213-222.e2.	0.2	26
229	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Review of Hematology, 2016, 9, 433-445.	1.0	9
230	CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma, 2016, 57, 1965-1968.	0.6	7
231	Relapsed Refractory BRAF-Negative, IGHV4-34â€“Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. Journal of Clinical Oncology, 2016, 34, e57-e60.	0.8	11
232	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood, 2016, 128, 3171-3171.	0.6	2
233	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood, 2016, 128, 757-757.	0.6	2
234	Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.. Journal of Clinical Oncology, 2016, 34, 7008-7008.	0.8	71

#	Article	IF	Citations
235	Phase I/II trial of the combination of midostaurin (PKC412) and 5â€azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 276-281.	2.0	139
236	A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica, 2015, 100, 231-237.	1.7	29
237	Identification of a Novel Fusion Gene,IRF2BP2-RARA, in Acute Promyelocytic Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 19-22.	2.3	46
238	Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. American Journal of Hematology, 2015, 90, E134-5.	2.0	4
239	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology, 2015, 90, 1065-1070.	2.0	17
240	Longâ€term followâ€up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with <scp>P</scp>hiladelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer, 2015, 121, 4158-4164.	2.0	181
241	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with allâ€trans retinoic acid and arsenic trioxide. British Journal of Haematology, 2015, 171, 471-477.	1.2	36
242	Characteristics, clinical outcome, and prognostic significance of <scp>IDH</scp> mutations in <scp>AML</scp>. American Journal of Hematology, 2015, 90, 732-736.	2.0	242
243	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773.	2.0	27
244	Monoclonal antibodies in acute lymphoblastic leukemia. Blood, 2015, 125, 4010-4016.	0.6	144
245	Novel therapeutic options for relapsed hairy cell leukemia. Leukemia and Lymphoma, 2015, 56, 2264-2272.	0.6	13
246	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology, 2015, 90, 27-30.	2.0	38
247	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 653-661.	1.7	191
248	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 2704-2714.	3.2	56
249	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	5.1	129
250	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leukemia Research, 2015, 39, 950-956.	0.4	69
251	Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood, 2015, 125, 3236-3245.	0.6	113
252	Toward Individualized Therapy in Acute Myeloid Leukemia. JAMA Oncology, 2015, 1, 820.	3.4	47

#	Article	IF	Citations
253	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 2015, 15, 365-373.	1.1	21
254	Final results of a phase 2 trial of clofarabine and lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer, 2015, 121, 2375-2382.	2.0	40
255	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. American Journal of Hematology, 2015, 90, 504-510.	2.0	33
256	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British Journal of Haematology, 2015, 168, 646-653.	1.2	64
257	Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxide. Leukemia and Lymphoma, 2015, 56, 1342-1345.	0.6	24
258	<scp>REVEAL</scp>â€1, a phase 2 dose regimen optimization study of vosaroxin in older poorâ€risk patients with previously untreated acute myeloid leukaemia. British Journal of Haematology, 2015, 168, 796-805.	1.2	27
259	Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. British Journal of Haematology, 2015, 170, 590-593.	1.2	15
260	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555.	5.1	245
261	Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions. Drugs and Aging, 2015, 32, 983-997.	1.3	16
262	Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S104-S108.	0.2	4
263	Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?. Lancet Oncology, The, 2015, 16, 1274-1275.	5.1	4
264	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.4	48
265	Chemoimmunotherapy for hairy cell leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 230-235.	0.7	11
266	Progress in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 139-151.	0.2	40
267	A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 171-176.	0.2	67
268	Phase II study of methotrexate, vincristine, pegylatedâ€asparaginase, and dexamethasone (<scp>MO</scp>p<scp>AD</scp>) in patients with relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2015, 90, 120-124.	2.0	21
269	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2541-2541.	0.6	7
270	Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. Blood, 2015, 126, 2560-2560.	0.6	1

#	Article	IF	Citations
271	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 461-461.	0.6	9
272	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. Blood, 2015, 126, 796-796.	0.6	12
273	FLT3 in AML. , 2015, , 215-231.		0
274	MutatedNPM1in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma, 2014, 55, 1337-1344.	0.6	28
275	Lack of association ofIDH1, IDH2andDNMT3Amutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leukemia and Lymphoma, 2014, 55, 1925-1929.	0.6	60
276	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica, 2014, 99, 465-473.	1.7	165
277	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. American Journal of Hematology, 2014, 89, 282-287.	2.0	58
278	Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to highâ€dose cytarabineâ€based induction chemotherapy. American Journal of Hematology, 2014, 89, 395-398.	2.0	49
279	Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?. Best Practice and Research in Clinical Haematology, 2014, 27, 241-246.	0.7	5
280	Acute myeloid leukemia in the elderly: do we know who should be treated and how?. Leukemia and Lymphoma, 2014, 55, 979-987.	0.6	36
281	Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging EntityÂWith a Poor Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 93-97.	0.2	14
282	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer, 2014, 120, 373-380.	2.0	54
283	Update on the Biology and Treatment Options for Hairy Cell Leukemia. Current Treatment Options in Oncology, 2014, 15, 187-209.	1.3	27
284	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2014, 23, 943-954.	1.9	27
285	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAGâ€GO) as frontâ€line regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 2014, 89, 964-968.	2.0	62
286	The bruton tyrosine kinase inhibitor ibrutinib (<scp>PCI</scp>â€32765) blocks hairy cell leukaemia survival, proliferation and <scp>B</scp> cell receptor signalling: a new therapeutic approach. British Journal of Haematology, 2014, 166, 177-188.	1.2	65
287	Treatment with FLT3 inhibitor in patients with FLT3â€mutated acute myeloid leukemia is associated with development of secondary FLT3â€“tyrosine kinase domain mutations. Cancer, 2014, 120, 2142-2149.	2.0	107
288	Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. Clinical Cancer Research, 2014, 20, 2363-2374.	3.2	45

#	Article	IF	Citations
289	Incorporating Tyrosine Kinase Inhibitors into Treatment Regimens for AML and ALL: Is There a Right or Wrong Way?. Current Hematologic Malignancy Reports, 2014, 9, 144-147.	1.2	2
290	Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to haveIDH1orIDH2mutations. Leukemia and Lymphoma, 2014, 55, 1431-1434.	0.6	4
291	A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 401-410.	0.2	51
292	Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e47-e49.	0.2	12
293	Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3671-3671.	0.6	3
294	Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR). Blood, 2014, 124, LBA-6-LBA-6.	0.6	14
295	Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival byÂBaseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 592-596.	0.2	8
296	Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncology, 2013, 9, 1073-1082.	1.1	14
297	Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 435-440.	0.2	26
298	Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia. Seminars in Hematology, 2013, 50, 271-283.	1.8	22
299	Relapsed acute myeloid leukemia: Why is there no standard of care?. Best Practice and Research in Clinical Haematology, 2013, 26, 253-259.	0.7	34
300	Treatment of Hairy Cell Leukemia During Pregnancy: Are Purine Analogues and Rituximab Viable Therapeutic Options. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 86-89.	0.2	21
301	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients â‰¥60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2013, 88, 961-966.	2.0	46
302	Significance of FAB subclassification of â€œacute myeloid leukemia, NOSâ€•in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood, 2013, 121, 2424-2431.	0.6	97
303	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. American Journal of Hematology, 2013, 88, 56-59.	2.0	82
304	â€œIt's effective therapy, stupid!â€• Leukemia Research, 2013, 37, 1434-1435.	0.4	1
305	Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 153-158.	0.2	13
306	Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 296-301.	0.2	50

#	Article	IF	Citations
307	Is there a standard induction regimen for patients with AML?. Lancet Oncology, The, 2013, 14, 565-566.	5.1	2
308	Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S289-S294.	0.2	2
309	Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 485-492.	0.2	25
310	Is acute myeloid leukemia a liquid tumor?. International Journal of Cancer, 2013, 133, 534-543.	2.3	47
311	Decitabine in Older Adults With Acute Myeloid Leukemia: Why Was the Dream Broken?. Journal of Clinical Oncology, 2013, 31, 1795-1796.	0.8	14
312	Novel treatment options for acute myelocytic leukemia. Clinical Investigation, 2013, 3, 979-990.	0.0	0
313	TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Modern Pathology, 2013, 26, 195-203.	2.9	19
314	Salvage therapy using <scp>FLT</scp>3 inhibitors may improve longâ€term outcome of relapsed or refractory <scp>AML</scp> in patients with <scp>FLT</scp>3â€<scp>ITD</scp>. British Journal of Haematology, 2013, 161, 659-666.	1.2	20
315	The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Frontiers in Oncology, 2013, 3, 218.	1.3	22
316	The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 327-335.	3.2	40
317	Treating adults with acute lymphoblastic leukemia: it is time to grow up. International Journal of Hematologic Oncology, 2013, 2, 5-8.	0.7	0
318	Detection of MRD may predict the outcome of patients with Philadelphia chromosomeâ€“positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood, 2013, 122, 1214-1221.	0.6	190
319	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662.	0.6	355
320	Acute Myeloid Leukemia, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1047-1055.	2.3	135
321	Expert Insights into the Contemporary Management of Older Adults with Acute Myeloid Leukemia. Cancer Control, 2013, 20, 5-16.	0.7	0
322	Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report. Blood, 2013, 122, 2686-2686.	0.6	1
323	Rapid Detection and Quantitation ofBRAFMutations in Hairy Cell Leukemia Using a Sensitive Pyrosequencing Assay. American Journal of Clinical Pathology, 2012, 138, 153-156.	0.4	37
324	Acute Myeloid Leukemia as a Model for Cancer Therapy. Frontiers in Oncology, 2012, 2, 139.	1.3	2

#	Article	IF	Citations
325	Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Modern Pathology, 2012, 25, 1405-1412.	2.9	48
326	Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. Future Oncology, 2012, 8, 351-357.	1.1	5
327	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Journal of Clinical Oncology, 2012, 30, 2204-2210.	0.8	158
328	Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leukemia and Lymphoma, 2012, 53, 1839-1841.	0.6	10
329	Gemtuzumab Ozogamicin: Time to Resurrect?. Journal of Clinical Oncology, 2012, 30, 3921-3923.	0.8	95
330	Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica, 2012, 97, 1242-1245.	1.7	41
331	Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1029-1036.	2.3	24
332	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012, 119, 1981-1987.	0.6	298
333	Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood, 2012, 119, 4614-4618.	0.6	178
334	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood, 2012, 120, 4840-4845.	0.6	193
335	Usefulness of CD11a and CD18 in Flow Cytometric Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia. American Journal of Clinical Pathology, 2012, 138, 744-750.	0.4	22
336	Inotuzumab ozogamicin, an anti-CD22â€“calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncology, The, 2012, 13, 403-411.	5.1	401
337	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 2670-2677.	0.8	998
338	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biology of Blood and Marrow Transplantation, 2012, 18, 584-592.	2.0	76
339	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 244-251.	0.2	34
340	Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research, 2012, 36, 1500-1504.	0.4	47
341	Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options. Current Oncology Reports, 2012, 14, 387-394.	1.8	83
342	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with highâ€dose cytarabine and idarubicin. Cancer, 2012, 118, 2665-2673.	2.0	47

#	Article	IF	Citations
343	Clofarabine plus lowâ€dose cytarabine followed by clofarabine plus lowâ€dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer, 2012, 118, 4471-4477.	2.0	60
344	Impact of numerical variation in FMSâ€like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer, 2012, 118, 5819-5822.	2.0	17
345	Acute promyelocytic leukemia: A populationâ€based study on incidence and survival in the United States, 1975â€2008. Cancer, 2012, 118, 5811-5818.	2.0	74
346	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. Journal of Clinical Oncology, 2012, 30, 2492-2499.	0.8	165
347	Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.. Blood, 2012, 120, 2630-2630.	0.6	11
348	The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leukemia and Lymphoma, 2011, 52, 94-98.	0.6	15
349	Chemo-immunotherapy for hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 72-74.	0.6	20
350	New Treatments and Strategies in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S60-S64.	0.2	1
351	Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 198-203.	0.2	16
352	Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 361-366.	0.2	30
353	Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib. Biology of Blood and Marrow Transplantation, 2011, 17, 1874-1877.	2.0	97
354	A potential role of ruxolitinib in leukemia. Expert Opinion on Investigational Drugs, 2011, 20, 1159-1166.	1.9	13
355	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 2011, 117, 3294-3301.	0.6	353
356	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood, 2011, 118, 4541-4546.	0.6	133
357	Therapy-related acute promyelocytic leukemia. Haematologica, 2011, 96, 493-495.	1.7	13
358	Primary refractory acute myeloid leukaemia â€“ in search of better definitions and therapies. British Journal of Haematology, 2011, 155, 413-419.	1.2	30
359	The Search for Better Prognostic Models in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2011, 6, 13-21.	1.2	11
360	Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2011, 6, 187-194.	1.2	22

#	Article	IF	Citations
361	Reply to Evaluation of PML Immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia. Cancer, 2011, 117, 435-436.	2.0	1
362	A phase 1â€2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2011, 117, 1236-1244.	2.0	36
363	Outcome of therapyâ€related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer, 2011, 117, 110-115.	2.0	32
364	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer, 2011, 117, 2145-2155.	2.0	91
365	FLT3 inhibitors in the treatment of acute myeloid leukemia. Cancer, 2011, 117, 3293-3304.	2.0	52
366	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica, 2011, 96, 62-68.	1.7	185
367	Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opinion on Emerging Drugs, 2011, 16, 407-423.	1.0	6
368	Gemtuzumab Ozogamicin: One Size Does Not Fit Allâ€"The Case for Personalized Therapy. Journal of Clinical Oncology, 2011, 29, 349-351.	0.8	30
369	Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 2507-2513.	0.8	62
370	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. Journal of Clinical Oncology, 2011, 29, 4417-4424.	0.8	287
371	Acute Myeloid Leukemia With IDH1 or IDH2 Mutation. American Journal of Clinical Pathology, 2011, 135, 35-45.	0.4	145
372	Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood, 2011, 118, 3818-3823.	0.6	103
373	Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy. Blood, 2011, 118, 1453-1453.	0.6	2
374	Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 1512-1512.	0.6	1
375	Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB). Blood, 2011, 118, 2578-2578.	0.6	17
376	Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology, 2011, 25, 741-3.	0.4	4
377	Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or highâ€risk myelodysplastic syndrome. Cancer, 2010, 116, 93-97.	2.0	21
378	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomeâ€"positive (Ph+) acute lymphoblastic leukemia. Blood, 2010, 116, 2070-2077.	0.6	319

#	Article	IF	Citations
379	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 2010, 116, 4422-4429.	0.6	336
380	Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood, 2010, 116, 5818-5823.	0.6	93
381	Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody. Cancer, 2010, 116, 369-376.	2.0	45
382	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 2010, 116, 3830-3834.	2.0	241
383	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer, 2010, 116, 5568-5574.	2.0	104
384	Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia. Cancer, 2010, 116, 5272-5278.	2.0	8
385	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leukemia Research, 2010, 34, 752-756.	0.4	102
386	Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Journal of Clinical Oncology, 2010, 28, 1766-1771.	0.8	187
387	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosomeâ€“Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3880-3889.	0.8	361
388	Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leukemia and Lymphoma, 2010, 51, 778-782.	0.6	52
389	Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 285-291.	0.8	70
390	Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy, 2010, 10, 9-22.	1.1	58
391	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1856-1862.	0.8	347
392	Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leukemia and Lymphoma, 2010, 51, 73-78.	0.6	38
393	Acute erythroleukemia: diagnosis and management. Expert Review of Hematology, 2010, 3, 705-718.	1.0	39
394	Treatment of Patients With Acute Promyelocytic Leukemia: A Consensus Statement on Risk-Adapted Approaches to Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S122-S126.	0.2	10
395	Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2010, , 165-176.		0
396	Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia. Blood, 2010, 116, 2127-2127.	0.6	7

#	Article	IF	Citations
397	Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. Journal of Clinical Oncology, 2009, 27, 5425-5430.	0.8	67
398	Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Leukemia and Lymphoma, 2009, 50, 27-31.	0.6	10
399	Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology, 2009, 27, 504-510.	0.8	355
400	T-Cell Large Granular Lymphocyte Leukemia Associated With Myelodysplastic Syndrome. American Journal of Clinical Pathology, 2009, 131, 347-356.	0.4	40
401	Therapyâ€related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer, 2009, 115, 101-106.	2.0	15
402	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer, 2009, 115, 2482-2490.	2.0	116
403	Survival is poorer in patients with secondary coreâ€binding factor acute myelogenous leukemia compared with de novo coreâ€binding factor leukemia. Cancer, 2009, 115, 3217-3221.	2.0	76
404	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and highâ€risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer, 2009, 115, 5746-5751.	2.0	93
405	Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. International Journal of Hematology, 2009, 89, 489-496.	0.7	50
406	Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2009, 15, 1431-1438.	2.0	58
407	Hairy Cell Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S254-S259.	1.4	4
408	Advances in treatment of chronic myelogenous leukemia â€“ new treatment options with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2009, 50, 16-26.	0.6	23
409	Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy. Leukemia and Lymphoma, 2009, 50, 1073-1074.	0.6	6
410	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America, 2009, 23, 1043-1063.	0.9	57
411	Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).. Blood, 2009, 114, 2043-2043.	0.6	6
412	A Prognostic Model of Therapy-Related Myelodysplastic syndrome .. Blood, 2009, 114, 3796-3796.	0.6	4
413	Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.. Blood, 2009, 114, 3819-3819.	0.6	2
414	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 2008, 113, 1351-1361.	2.0	458

#	Article	IF	Citations
415	Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer, 2008, 113, 2090-2096.	2.0	52
416	Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer, 2008, 113, 2097-2101.	2.0	109
417	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer, 2008, 113, 3186-3191.	2.0	129
418	Treatment of coreâ€bindingâ€factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colonyâ€stimulating factor results in improved eventâ€free survival. Cancer, 2008, 113, 3181-3185.	2.0	68
419	Potential role of sorafenib in the treatment of acute myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 2246-2255.	0.6	48
420	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica, 2008, 93, 1263-1265.	1.7	40
421	Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leukemia and Lymphoma, 2008, 49, 690-695.	0.6	106
422	High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood, 2008, 111, 328-337.	0.6	120
423	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2008, 112, 1638-1645.	0.6	199
424	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosomeâ€“positive leukemias. Blood, 2008, 112, 5190-5192.	0.6	36
425	Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood, 2008, 111, 1816-1819.	0.6	92
426	Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).. Blood, 2008, 112, 1931-1931.	0.6	10
427	Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB). Blood, 2008, 112, 2919-2919.	0.6	4
428	Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2921-2921.	0.6	5
429	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 2007, 109, 4679-4685.	0.6	303
430	Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia. Journal of Clinical Oncology, 2007, 26, 25-31.	0.8	75
431	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007, 109, 52-57.	0.6	675
432	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2007, 110, 2302-2308.	0.6	391

#	Article	IF	Citations
433	Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer, 2007, 109, 713-717.	2.0	120
434	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer, 2007, 109, 1133-1137.	2.0	182
435	Progress in the treatment of acute myeloid leukemia. Cancer, 2007, 110, 1900-1910.	2.0	80
436	T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years. Leukemia Research, 2007, 31, 939-945.	0.4	41
437	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60â€ƒyears of age receiving induction therapy for acute myeloid leukaemia.. British Journal of Haematology, 2007, 136, 624-627.	1.2	223
438	Modern treatment programs for adults with acute lymphoblastic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 169-175.	1.2	1
439	Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.. Blood, 2007, 110, 441-441.	0.6	4
440	Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.. Blood, 2007, 110, 897-897.	0.6	15
441	Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opinion on Investigational Drugs, 2006, 15, 1601-1613.	1.9	40
442	Purine Analogues in Advanced T-Cell Lymphoid Malignancies. Seminars in Hematology, 2006, 43, S27-S34.	1.8	12
443	Monoclonal Antibody Therapy for Hairy Cell Leukemia. Hematology/Oncology Clinics of North America, 2006, 20, 1125-1136.	0.9	9
444	Phase 1/2 study of the combination of 5-aza-2â€²-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, 108, 3271-3279.	0.6	492
445	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood, 2006, 108, 45-51.	0.6	146
446	Eradication of minimal residual disease in hairy cell leukemia. Blood, 2006, 107, 4658-4662.	0.6	120
447	Survival benefit with imatinib mesylate versus interferon-Î±â€“based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 2006, 108, 1835-1840.	0.6	204
448	Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 2006, 108, 2392-2398.	0.6	81
449	Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leukemia Research, 2006, 30, 103-105.	0.4	32
450	Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy, 2006, 55, 197-209.	2.0	117

#	Article	IF	Citations
451	Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer, 2006, 106, 1794-1803.	2.0	1,447
452	Alemtuzumab in CLL and Other Lymphoid Neoplasms. Cancer Investigation, 2006, 24, 718-725.	0.6	37
453	Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia: Fig. 1.. Clinical Cancer Research, 2006, 12, 340-344.	3.2	58
454	Treatment of acute myeloid leukemia in older adults: time to reflect?. Leukemia and Lymphoma, 2006, 47, 579-80.	0.6	0
455	Infections associated with purine analogs and monoclonal antibodies. Blood Reviews, 2005, 19, 253-273.	2.8	19
456	Mature T-cell leukemias. Cancer, 2005, 104, 1808-1818.	2.0	28
457	Alemtuzumab. Expert Review of Anticancer Therapy, 2005, 5, 39-51.	1.1	52
458	Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 1660-1674.	1.4	35
459	T-Cell Prolymphocytic Leukemia: A Single-Institution Experience. Clinical Lymphoma and Myeloma, 2005, 6, 234-239.	1.4	31
460	Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 2119-2119.	0.6	1
461	Forodesine (FodosineTM), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).. Blood, 2005, 106, 881-881.	0.6	5
462	New agents in acute myeloid leukemia and other myeloid disorders. Cancer, 2004, 100, 441-454.	2.0	39
463	Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer, 2003, 97, 1242-1247.	2.0	49
464	Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. Leukemia Research, 2003, 27, 853-857.	0.4	9
465	Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clinical Cancer Research, 2003, 9, 535-50.	3.2	28
466	CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY. British Journal of Haematology, 2002, 116, 57-77.	1.2	25